• following withdrawal of doxycycline and intrasplenic injection of adenovirus expressing Cre recombinase, adult liver cells exhibit an increase in polyploidy

• median survival of mutants is 27 weeks following withdrawal of doxycycline and intrasplenic injection of adenovirus expressing Cre recombinase

• median survival of mutants with tumors is 16.5 weeks following withdrawal of doxycycline and intrasplenic injection of adenovirus expressing Cre recombinase

• following withdrawal of doxycycline and intrasplenic injection of adenovirus expressing Cre recombinase, some mice develop liver tumors composed of multiple fleshy vascular nodules

• tumors of mice injected with adenovirus expressing Cre recombinase and without doxycycline to induce MYC expression are composed of hepatocellular neoplasms characterized by sheets of cells with occasional mitotic figure, slightly pleomorphic nuclei, and prominent nucleoli

• tumors show a range of differentiation between well- and moderately-differentiated hepatocellular carcinoma

• incidence of T cell lymphomas is similar to that in transgenic mice wild-type for Trp53bp2

• following induction with doxycycline, mice develop glomerular cysts

• following induction with doxycycline, mice develop multiple renal cysts in all renal tubular compartments

• 3 to 4 months following induction with doxycycline

• following induction with doxycycline, mice develop renal adenomas

• following induction with doxycycline

• following withdrawal of doxycycline, all mice succumb to liver tumors within 2 weeks (J:93899)

• median survival of mutants is 31 weeks following doxycycline withdrawal to induce MYC expression (J:172430)

• median survival of mutants with tumors is 27 weeks following doxycycline withdrawal to induce MYC expression (J:172430)

• doxycycline-treated mice infected with an adeno-associated virus-expressing Mir122 exhibit suppression of tumorigenesis tumor cell proliferation compared with control mice

• following withdrawal of doxycycline, mice develop tumors with a latency of 12 weeks and all mice succumb to liver tumors within 2 weeks (J:93899)

• liver tumors that develop in mice after doxycycline withdrawal are invasive and metastasis into the thoracic cavity and lung parenchyma (J:93899)

• however, re-establishment of doxycycline-treatment produces rapid and sustained tumor regression (J:93899)

• repeated withdrawal and treatment with doxycyclineinduces and represses, respectively, tumor formation (J:93899)

• liver tumors that develop in mice after doxycycline withdrawal resemble hepatocellular carcinomas and/or hepatoblastomas

• liver tumors that develop in mice after doxycycline withdrawal resemble hepatocellular carcinomas and/or hepatoblastomas (J:93899)

• tumors that form in mice after doxycycline withdrawal are composed of hepatocellular neoplasms characterized by sheets of cells with occasional mitotic figure, slightly pleomorphic nuclei, and prominent nucleoli (J:172430)

• tumors show a range of differentiation between well- and moderately-differentiated hepatocellular carcinoma (J:172430)

• in doxycycline-treated mice (J:190067)

• however, treatment with adeno-associated virus-expressing Mir122 suppresses tumorigenesis (J:190067)